145 related articles for article (PubMed ID: 26032985)
1. Campaigners challenge patent applications for hepatitis C drug in five countries.
Bagcchi S
BMJ; 2015 Jun; 350():h2938. PubMed ID: 26032985
[No Abstract] [Full Text] [Related]
2. Hepatitis C drugs not reaching poor.
Callaway E
Nature; 2014 Apr; 508(7496):295-6. PubMed ID: 24740042
[No Abstract] [Full Text] [Related]
3. Gilead injects own generics into shrinking HCV drug market.
Morrison C
Nat Biotechnol; 2018 Nov; 36(11):1030. PubMed ID: 30412188
[No Abstract] [Full Text] [Related]
4. China rejects patent on hepatitis C drug sofosbuvir.
Kmietowicz Z
BMJ; 2015 Jun; 350():h3429. PubMed ID: 26105994
[No Abstract] [Full Text] [Related]
5. Dare to refuse the exorbitant price of Sovaldi!
Prescrire Int; 2014 Nov; 23(154):278. PubMed ID: 25954802
[No Abstract] [Full Text] [Related]
6. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
Cohen J
Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
[No Abstract] [Full Text] [Related]
7. Medicine. Hepatitis C can be cured globally, but at what cost?
Hill A; Cooke G
Science; 2014 Jul; 345(6193):141-2. PubMed ID: 25013048
[No Abstract] [Full Text] [Related]
8. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.
Phelan M; Cook C
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S5. PubMed ID: 25253373
[No Abstract] [Full Text] [Related]
9. Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
Mattingly Ii TJ; Heil EL; Hoke KS
J Health Care Poor Underserved; 2017; 28(2):621-625. PubMed ID: 28529212
[TBL] [Abstract][Full Text] [Related]
10. Guideline: New HCV drugs should go to sickest patients.
Kuehn BM
JAMA; 2014 Sep; 312(11):1084-5. PubMed ID: 25226461
[No Abstract] [Full Text] [Related]
11. Screening urged for hepatitis C but drug costs are prohibitive.
Fralick M
CMAJ; 2014 Mar; 186(5):329. PubMed ID: 24549123
[No Abstract] [Full Text] [Related]
12. US health insurers say Gilead hepatitis C drug too costly.
Clin Infect Dis; 2014 Jul; 59(2):i-ii. PubMed ID: 25105185
[No Abstract] [Full Text] [Related]
13. Brazil's Fight against Hepatitis C - Universalism, Local Production, and Patents.
da Fonseca EM; Shadlen K; Bastos FI
N Engl J Med; 2019 Feb; 380(7):605-607. PubMed ID: 30763192
[No Abstract] [Full Text] [Related]
14. WHO issues guidelines on HCV amid drug cost controversy.
Slomski A
JAMA; 2014 Jun; 311(22):2262-3. PubMed ID: 24915242
[No Abstract] [Full Text] [Related]
15. Universal Medicine Access through Lump-Sum Remuneration - Australia's Approach to Hepatitis C.
Moon S; Erickson E
N Engl J Med; 2019 Feb; 380(7):607-610. PubMed ID: 30763190
[No Abstract] [Full Text] [Related]
16. Payers consider waiting out budget-busting hepatitis C drug.
Carroll J
Manag Care; 2014 May; 23(5):7, 9. PubMed ID: 25016845
[No Abstract] [Full Text] [Related]
17. Sovaldi dilemma likely to get worse.
Carroll J
Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
[No Abstract] [Full Text] [Related]
18. Take a Bow, Pharma, for the Hepatitis C Drugs.
Reinke T
Manag Care; 2018 Apr; 27(4):12-13. PubMed ID: 29701579
[TBL] [Abstract][Full Text] [Related]
19. Oseltamivir becomes plentiful--but still not cheap.
Enserink M
Science; 2006 Apr; 312(5772):382-3. PubMed ID: 16627733
[No Abstract] [Full Text] [Related]
20. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries.
Ghinea N; Lipworth W; Day R; Hill A; Dore GJ; Danta M
Lancet; 2017 Mar; 389(10075):1268-1272. PubMed ID: 27832868
[No Abstract] [Full Text] [Related]
[Next] [New Search]
